ArticleAnnals of surgical oncology2025
Exploring the Role of CDO1 in Breast Cancer: Insights into Tumor Biology and Therapeutic Potential.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification of immune and ferroptosis-related gene cysteine dioxygenase type 1 (CDO1) as a prognostic biomarker in colorectal cancer, relating to immunotherapy response distinction.World journal of surgical oncology · 2026Article
- Machine learning-based determination of sex-related bladder cancer biomarkers.Frontiers in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BC) is a heterogeneous disease with variable prognosis, highlighting the need for novel biomarkers and therapeutic targets. This study investigates the role of the CDO1 gene, which encodes cysteine dioxygenase 1, in BC progression and its potential impact on patient outcomes. MATERIALS AND
methodsWe performed stable transfection of CDO1 in the MDA-MB231 triple negative BC (TNBC) cell line, followed by analysis of gene expression profiles using microarray technology.
resultsCDO1 is significantly upregulated in transfected cells, leading to the induction of several tumor suppressor genes, including DEFB1, HOPX, and FRMD3. Correlation analysis in clinical BC samples revealed significant associations between CDO1 and other key genes, including SLC1A7 and KITLG, underscoring its relevance in tumor biology. Functional assays demonstrated that CDO1 expression is associated with increased apoptosis and reduced cell viability, suggesting a protective role against tumor progression. Additionally, we observed alterations in oncogenic pathways related to extracellular matrix and protease (SGRN and ADAMTS1), indicating that CDO1 may alleviate metastatic potential putatively via stromal reprogramming.
conclusionsOur findings establish CDO1 as a significant modulator of BC behavior and highlight its potential as a biomarker for prognosis. Further research is warranted to elucidate the underlying mechanisms and explore the therapeutic implications of targeting CDO1 in TNBC.
Indexed as
Identifiers
40762777What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.